Summary

Risk Factors

Our business is subject to numerous risks and uncertainties that you should consider before investing in our company. Key risk factors include:

Risks Related to Our Intellectual Property

• We depend on rights to Telomir-1 that are or will be licensed to us. We do not own the intellectual property rights to Telomir-1 and any loss of our rights to it could prevent us from selling our product.
• We may not be able to adequately protect our product candidates or our proprietary technology in the marketplace.
• If third parties claim that our intellectual property, products, processes, or anything else used by us infringes upon their intellectual property, our operating profits could be adversely affected.
• We have been granted a license to the right to develop Telomir-1 in the United States in human and pet application, but we have not been granted a license to the rights to patents covering Telomir-1 in foreign jurisdictions.

Risks Related to Our Operations and Financial Condition

• We are an early development-stage company with no revenues and our financial condition raises substantial doubt as to our ability to continue as a going concern.
• Because we have a limited operating history, you may not be able to accurately evaluate our operations.
• We will need to raise additional financing for the continuation of our operations.
• Our operating results may fluctuate, which could have a negative impact on our ability to grow our client base, establish sustainable revenues and succeed overall.
• We have yet to achieve a profit and will not achieve a profit in the near future, if at all.
• Certain of our executive officers are not employed by us on a full-time basis.
• Conflicts of interest may arise between us and MIRALOGX.

Risks Relating to Our Business and Our Industry

• Our future success will largely depend on the success of Telomir-1 and any future product candidates, which development will require significant capital resources and years of clinical development effort.
• We are dependent on our current and future product candidates, some of which may not receive regulatory approval or be successfully commercialized.
• Results of pre-clinical studies and earlier clinical trials are not necessarily predictive indicators of future results.
• We have limited marketing experience, and we do not anticipate at this time establishing a sales force or distribution and reimbursement capabilities, and we may not be able to successfully commercialize any of our product candidates if they are approved in the future.
• We will need to further increase the size and complexity of our organization in the future, and we may experience difficulties in managing our growth and executing our growth strategy.
• We expect to face intense competition, often from companies with greater resources and experience than we have.
• We have significant and increasing liquidity needs and may require additional funding.

The article provides a comprehensive overview of the key risk factors facing the company, covering intellectual property, operations, finances, business and industry, and regulatory issues. It highlights the company’s dependence on licensed technology, the need for additional financing, the challenges of developing and commercializing new products, and the competitive landscape. The risks outlined demonstrate the speculative and high-risk nature of investing in this early-stage pharmaceutical company.